血管内皮生长因子(vascular endothelial growth factor,VEGF)家族及其受体已被公认在促进血管生成中起关键作用,大量研究证实其与肿瘤生长及血管生成具有相关性。胎盘生长因子(placental growth factor,PlGF)为VEGF家族的一个成员,与其受体VEGFR-1可以通过特异性结合而产生生物学活性。PlGF在正常组织中几乎不表达,但在病理条件下,其在一些细胞中表达增加。在肿瘤生长和血管生成的基础研究中,PlGF的作用备受争议。PlGF在人类多种肿瘤组织中表达,并且在部分肿瘤中其表达水平与预后不良相关。抗PlGF治疗可抑制血管生成及肿瘤细胞生长。同抗VEGF治疗相比,抗PlGF治疗副作用较小,而且不损害健康血管。现就PlGF及其与肿瘤相关研究予以综述。 The vascular endothelial growth factor (VEGF) family and its receptors have been recognized as playing a key role in promoting angiogenesis. A large number of studies have shown that VEGF is associated with tumor growth and angiogenesis. Placental growth factor (placental growth factor, PlGF) is a member of the VEGF family and its receptor VEGFR-1 can be produced through the specific binding of biological activity. PlGF is almost not expressed in normal tissues, but its expression is increased in some cells under pathological conditions. The role of PlGF is controversial in basic research on tumor growth and angiogenesis. PlGF is expressed in many human tumor tissues, and its expression level is correlated with poor prognosis in some tumors. Anti-P1GF treatment can inhibit angiogenesis and tumor cell growth. Compared with anti-VEGF treatment, anti-PlGF treatment less side effects, and does not damage healthy blood vessels. PlGF and its tumor-related research are reviewed.